Access comprehensive financial analyses and make smarter investments - get the Manual of Investments on Amazon!

BK

Bank of New York Mellon Q1 2025 – Revenue Up 6%

The Bank of New York Mellon Corporation (“BNY”) (NYSE: BK) has reported its financial results for the first quarter of 2025. The bank delivered a solid performance with total revenue of $4.8 billion, representing a 6% increase year-over-year. The diluted earnings per common share stood at $1.58, marking a 26% increase over the same period last year.

In terms of financial highlights, total fee revenue decreased by 3% to $3.403 billion, while investment and other revenue increased to $230 million. Net interest income experienced a 11% growth, reaching $1.159 billion. Noninterest expense increased by 2% to $3.252 billion. The provision for credit losses stood at $18 million. Net income applicable to common shareholders increased by 2% to $1.149 billion, with diluted earnings per share growing by 3% to $1.58.

Key financial ratios and metrics also showed positive trends. The pre-tax operating margin reached 32%, up from 29% in the same period last year. Return on equity (ROE) increased to 12.6% from 10.7%, and return on tangible common equity (ROTCE) increased to 24.2% from 20.7%. The tier 1 leverage ratio and CET1 ratio also showed improvements.

The bank returned $1.1 billion of capital to common shareholders, including $343 million in dividends and $746 million in share repurchases, resulting in a total payout ratio of 95% year-to-date.

The securities services business segment saw total revenue decrease by 1% to $4.792 billion, with an improvement in pre-tax operating margin to 31% from 28%. The investment and wealth management business segment reported a total revenue decrease of 11% to $779 million, with a decrease in pre-tax operating margin to 8% from 20%.

Following these announcements, the company's shares moved 2.2%, and are now trading at a price of $78.26. If you want to know more, read the company's complete 8-K report here.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.

IN FOCUS